D&M Company Holds Study Sessions and Shares Insights on Fiscal 2026 Medical Fee Revisions

D&M Company (Headquarters: Kita-ku, Osaka; Representative Director: Akiyoshi Matsushita; Securities Code: 189A) conducted study sessions and documentation sharing regarding the fiscal 2026 medical fee revisions for its consulting clients from April to May 2026.

This initiative aimed to help clients gain an early understanding of the overall picture of the fiscal 2026 medical fee revisions, grasp their impact on operations, and consider future responses. The sessions covered the background and fundamental concepts of the revisions, clarified key points and changes in calculation requirements and facility standards, and provided explanations on the implications for medical institution management.

D&M Company analyzes and diagnoses clients' management challenges from multiple angles, formulates plans for sustainable development together with management, and provides hands-on consulting support for execution. To achieve this, the company offers a one-stop suite of services: 'F&I (Finance & Investment) Services' for the financial and investment sectors, 'C&Br (Consulting & Business Renovation) Services' to support management and business structure transformation, and 'HR&OS (Human Resources & Outsourcing) Services' to support the optimization of personnel and operational systems.

In this study session, the medical fee revision was not treated merely as a system change, but information was shared from the perspective of how to reflect it in management across financial, operational, and human resource aspects. The company will continue to monitor the latest developments in medical policies and provide consistent support from management strategy formulation to execution, contributing to the sustainable growth of medical institutions.